Bio-Techne's stock plummeted 5.15% during intraday trading on Friday.
The decline follows price target reductions from at least two analysts. Deutsche Bank cut its target on Bio-Techne to $66 from $75, while maintaining a buy rating. Separately, Stephens adjusted its price target to $68 from $80.
According to FactSet data, Bio-Techne has an average rating of overweight. The analyst actions likely contributed to the negative investor sentiment and selling pressure during the session.